

## **Acquisition Of Debiopharm's Investment Portfolio Company Kaiku Health Broadens Patient Access To Digital Oncology Intervention**

- *Debiopharm announces successful exit deal for Kaiku Health, a Finnish start-up specializing in digital solutions for improved patient outcomes and experience*
- *Kaiku's acquisition by the Swedish company Elekta allows thousands of cancer treatment centers to gain access to the start-up's novel digital patient monitoring platform*

**Lausanne, Switzerland– May 26, 2020** – Debiopharm ([www.debiopharm.com](http://www.debiopharm.com)), a Swiss biopharmaceutical company, announced today the successful exit and acquisition of their investment portfolio company Kaiku Health, a Helsinki-based digital therapeutics company specializing in improving the quality of life of cancer patients. The acquisition made by the publicly traded, Stockholm-based company Elekta (EKTA-B.ST), one of the global market leaders in precision radiation medicine, enables a reach to over 4000 oncology centers managing thousands of cancer patients worldwide with Elekta's software suite, extending the company's digital health offering.

In 2018, Debiopharm became the Series A lead investor in Kaiku Health in order to support the active adoption of their technology by hospitals, clinics, and pharmaceutical companies. The investment decision aligned with Debiopharm's vision is to invest in start-ups that change the way that patients are treated and the way that drugs are developed. The corporate fund specializes in disruptive digital health investments while actively helping the companies bring their technologies to a clinical reality.

*It's really thrilling to see our start-up investment companies grow and move to the next step of reaching more of the patients who can benefit from their innovation" **explained Tanja Dowe, CEO of Debiopharm Innovation Fund SA and former Chairwoman of Kaiku Health.** "The growing patient base through Elekta will strengthen Kaiku Health's capabilities to develop patient-centric and outcome-driven solutions for cancer patients, in some cases in collaboration with pharmaceutical companies. In the era of precision medicine, these outcomes play an important role for the development of pharmaceutical therapies."*

Debiopharm remains an active investor in digital health start-ups around the world. As the chairwoman of the board, Debiopharm Innovation Fund SA CEO, Tanja Dowe provided strategic and practical guidance to sustain and grow the start-up's network, pharmaceutical know-how and international impact.

Kaiku Health has been particularly implicated in immuno-oncology, where faster detection of predictive symptoms can lead to improved toxicity management. The platform offers cancer patients the ability to stay better connected to their medical team during and after therapy. This is accomplished via a user-friendly app that captures the experience and symptoms of patients through basic health-related questions. The patient-reported information allows caregivers to assess the effectiveness of treatments promptly, to detect and treat health issues early and to

adapt the treatment regimen immediately if necessary and can in addition be used to improve clinical study experience. Research shows that digital monitoring can have a beneficial effect on patient health comparable to that of a new medication, revealing the potential impact of this affordable, easy-to-use technology.

*“Personalized digital health intervention to every cancer patient – this has been our vision from the very beginning. Measuring what matters to patients is paramount for value-based healthcare,” expressed **Lauri Sippola, CEO of Kaiku Health**. “We are grateful for Debiopharm’s active support in developing our digital therapeutics pipeline as our Series A lead investor in 2018. We are encouraged that through this acquisition by Elekta, that now even more patients can have the possibility to receive more personalized cancer care through Kaiku technology.”*

Recently, Kaiku Health’s interventions have also been implemented to support the efficient monitoring of COVID-19 patients, including a specific symptom monitoring module in co-operation with the leading Swiss university hospital group, the Geneva University Hospitals (HUG).

### **About Kaiku Health**

Kaiku Health is a Class 1 Medical Device in cancer care, providing digital health interventions based on patient-reported outcomes. Kaiku Health has modules for over 25 cancer types across different cancer care pathways. It is currently in use in over 40 European cancer clinics and hospitals. For more information, please visit [www.kaikuhealth.com](http://www.kaikuhealth.com) and connect with us at Twitter @KaikuHealth.

### **About Elekta**

For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit [elekta.com](http://elekta.com) or follow [@Elekta](https://twitter.com/Elekta) on Twitter.

### **About Debiopharm**

Debiopharm develops, manufactures and invests in innovative therapies and technologies that respond to high unmet medical needs in oncology and bacterial infections. We aim to provide strategic funding and guidance for companies with Smart Data & Digital Health solutions with the ambition to change the way drugs are developed and the way patients are treated. Our growing portfolio company achievements includes 18 FDA clearances or CE marks and 2 IPOs. Since 2008, the company has invested nearly USD 100 millions and led 10 out of the 14 last investment rounds in its portfolio companies.

For more information, please visit [www.debiopharm.com](http://www.debiopharm.com)

We are on Twitter. Follow us [@DebiopharmNews](https://twitter.com/DebiopharmNews) and [@debiopharmfund](https://twitter.com/debiopharmfund)

**Debiopharm Contact****Dawn Haughton - Communication Manager**

dawn.haughton@debiopharm.com

Tel: +41 (0)21 321 01 11